Voltage-gated potassium channel (VGKC)-complex antibodies against unique neuronal surface antigens in the brain is a rapidly expanding category of adult autoimmune brain disease with central (CNS), peripheral (PNS) and autonomic nervous system (ANS) neuroimmunologic manifestations. The Mayo Clinic is an excellent resource for serum and cerebrospinal fluid testing to demonstrate the presence of the causative antibody as described in a recent publication by this author (http://file.scirp.org/pdf/WJNS_2016122314100487.pdf). Immune modulatory therapy including IVIg is first-line treatment in the acute and long-term management of this disorder employing a dose of 1.6 to 2 grams per kilogram (g/kg) per month administered over 2 to 4 days with careful monitoring for any side-effects.  

Seasonal Greetings and appreciation, 

David S Younger MD MPH MS